Lantheus Holdings Inc (LNTH)

Sep 26, 2026

Lantheus Holdings (LNTH) recently received FDA approval for BRAVNETSA, a radiopharmaceutical for adult GEP NET patients, which has brought the company into focus. Despite recent short-term share price pressure, LNTH has shown strong long-term returns, with a 48.27% year-to-date return and 97.08% 1-year total shareholder return. The article suggests the stock is currently 7% undervalued based on its pipeline, deal structure with Curium, and long-term cash generation potential, projecting a fair value of $107 per share.

Sep 23, 2026

Lantheus Holdings, Inc. received final FDA approval for Bravnetsa (PNT2003), a radiopharmaceutical therapeutically equivalent to Lutathera, for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The approval comes as Lantheus prepares for a shareholder vote on its sale to Curium. While Bravnetsa's launch date and price are undisclosed, the approval secures Lantheus's position in the adult GEP-NET market ahead of the merger decision.

Sep 23, 2026

Lantheus Holdings, Inc. (LNTH) has experienced a significant rally driven by strong quarterly earnings, FDA approval for PYLARIFY TruVu, and intensified takeover interest from PE-backed Curium Pharma. The company's shares gained 92.62% over the past 52 weeks, with a market capitalization of $6.55 billion. Polaris Capital Management's Global Equity Strategy highlighted LNTH's strong performance, although it noted that certain AI stocks might offer greater upside potential.